Natco Pharma acquires 35.75% stake in Adcock Ingram for USD 226 million

Written By :  Ruchika Sharma
Published On 2025-11-12 10:42 GMT   |   Update On 2025-11-12 10:42 GMT
Advertisement

Natco Pharma Limited has announced the successful completion of the delisting of Adcock Ingram Holdings Limited, one of South Africa’s oldest pharmaceutical companies, from the Johannesburg Stock Exchange (JSE).

This event marks the culmination of a strategic acquisition in which NATCO Pharma has acquired 35.75% of Adcock Ingram in a transaction valued at approximately USD 226 million (ZAR 4 billion).
Advertisement
In July 2025, Natco Pharma offered ZAR 75 (US$ 4.36) per share to acquire Adcock Ingram's minority shareholders, a proposal that was approved in October 2025 with thumping support from the shareholders. With the completion of this acquisition of stake, Natco Pharma attains market presence in South Africa.
"Natco Pharma aims to leverage Adcock Ingram’s established market position and consumer trust and expand its product offerings further in South Africa and beyond," the company stated in a BSE filing.
Rajeev Nannapaneni, CEO, Natco Pharma stated, “This acquisition represents a significant step in our strategic growth plan across the globe. We are committed to preserving the rich legacy of Adcock Ingram while enhancing its capabilities to better serve the healthcare needs of communities across Africa and beyond.”

Read also: Natco Gets SC Nod to Launch Generic Risdiplam at 80% Lower Price, Roche Appeal Dismissed

NATCO Pharma Limited is a public limited company, listed on the Bombay Stock Exchange and the National Stock Exchange of India, with a market capitalisation of c. US$ 2 billion. Established in 1981, NATCO Pharma has evolved into a diversified pharmaceutical manufacturer, with a primary focus on research and development, manufacturing, and global marketing of both finished dosage formulations and active pharmaceutical ingredients. NATCO Pharma operates across various geographies (in over 50 countries), including emerging and developed markets, with a particular focus on delivering quality medicines in oncology, cardiology, neurology, and other high-value therapeutic categories.

Read also: Natco Pharma appoints G Vijay Kiran Kumar as VP- Corporate Quality Assurance (Formulations)

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News